("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and ...

The Securities and Exchange Commission (SEC) has been recognized as global leader in good governance for the fifth straight ...

The Securities and Exchange Commission (SEC) said Wednesday it revoked the corporate registration and financing license of ...

The BC Securities Commission says a Vancouver cryptocurrency firm has been temporarily banned from trading securities and ...

-Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Algorhythm Holdings, Inc. ( NASDAQ: RIME) Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ET Gary Atkinson – Chief Executive Officer Alex Andre – Chief Financial Officer and General Counsel ...

Q1 2025 Earnings Call Transcript May 13, 2025 Intellicheck, Inc. beats earnings expectations. Reported EPS is $-0.02, ...

As of March 31, 2025, the Company’s cash, cash equivalents and investments was $314.2 million. The Company expects that its cash, cash equivalents and investments, as of March 31, 2025, will fund its ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30 th, 2025 ...

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination ...